Chrisanthi A. Karanikas

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock, Carol Wysham, Juan P. Frías et al. · The Lancet · 2021 · 907 citations

Metabolic Syndrome, Diabetes Management, Diabetes +6

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Mark L. Hartman, Arun J. Sanyal, Rohit Loomba et al. · Diabetes Care · 2020 · 321 citations · Full text

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Tim Heise, J. Hans DeVries, Shweta Urva et al. · Diabetes Care · 2023 · 169 citations · Full text

Adolescent Binge Drinking Leads to Changes in Alcohol Drinking, Anxiety, and Amygdalar Corticotropin Releasing Factor Cells in Adulthood in Male Rats

Nicholas W. Gilpin, Chrisanthi A. Karanikas, Heather N. Richardson · PLoS ONE · 2012 · 147 citations · Full text

Substance Use, Behavioral Addiction, Psychology +18

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

N. Mylonakis, A E Athanasiou, Nikolaos Ziras et al. · Lung Cancer · 2009 · 96 citations

Liposomal Cisplatin, Medicine, Pathology +7